The Role of Immune Cells in the Tumor Microenvironment

  • Theresa L. Whiteside
Part of the Cancer Treatment and Research book series (CTAR, volume 130)

Abstract

Interactions between tumor infiltrating leukocytes and tumor cells have been of great interest because of the possibility that immune cells either interfere with tumor progression or actively promote tumor growth. The tumor microenvironment is shaped by cells entering it, and their functions reflect the local conditions. Successive changes occurring at the tumor site during tumor progression resemble chronic inflammation. This chronic inflammatory reaction seems to be largely orchestrated by the tumor, and it seems to promote tumor survival. Molecular and cellular mechanisms linking the inflammatory reaction and cancer are emerging, and this review summarizes the current understanding of interactions between inflammatory and cancer cells in the tumor microenvironment.

Keywords

TIL immune evasion immune surveillance inflammation cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

5. References

  1. Albers, A.E. et al. (2005). Immune response to p53 in patients with cancer: enrichment in tetramer+p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol, Immunother. in press.Google Scholar
  2. Albers, A.E. et al. (2005). T-cell receptor variable gene β-restricted T lymphocytes are sensitive to apoptosis in patients with squamous cell carcinoma of the head and neck. Submitted.Google Scholar
  3. Aller, M.A. et al. (2004). Posttraumatic inflammation is a complex response based on the pathological expression of the nervous, immune and endocrine function systems. Exp. Biol. Med. 229: 170–181.Google Scholar
  4. Almand, B. et al. (2000). Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6: 1755–1766.PubMedGoogle Scholar
  5. Almand, B. et al. (2001). Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166: 678–689.PubMedGoogle Scholar
  6. Al-Sarireh, B. and Eremin, O. (2000). Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. J. R. Coll. Surg. Edinb. 45: 1–16.PubMedGoogle Scholar
  7. Baeuerle, P.A. and Baltimore, D. (1996). NF-kappaB: ten years after. Cell 87: 13–20.PubMedCrossRefGoogle Scholar
  8. Balkwill, F. and Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet 357: 539–545.PubMedCrossRefGoogle Scholar
  9. Balkwill, F. (2004). Cancer and the chemokine network. Nat. Rev. Cancer 4: 540–550.PubMedCrossRefGoogle Scholar
  10. Balkwill, F. and Coussens, L.M. (2004). Cancer: An inflammatory link. Nature 431: 405–406.PubMedCrossRefGoogle Scholar
  11. Bamias, A. and Dimipoulos, M.A. (2003). Angiogenesis in human cancer: implications in cancer therapy. Eur. J. Intern. Med. 14: 459–469.PubMedCrossRefGoogle Scholar
  12. Banchereau, J. and Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature 392: 245–252.PubMedCrossRefGoogle Scholar
  13. Banchereau, J. et al. (2000). Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767–811.PubMedCrossRefGoogle Scholar
  14. Baxevanis, C.N. et al. (1994). Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74: 1275–1282.PubMedCrossRefGoogle Scholar
  15. Becker, Y. (1993). Dendritic cell activity against primary tumors: an overview. In Vivo 7: 187–191.PubMedGoogle Scholar
  16. Bogenrieder, T. and Herlyn, M. (2003). Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22: 6524–6536.PubMedCrossRefGoogle Scholar
  17. Borregaard, N. and Herlin T. (1982). Energy metabolism of human neutrophils during phagocytosis. J. Clin. Invest. 70: 550–557.PubMedCrossRefGoogle Scholar
  18. Coronella, J.A. et al. (2001). Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res. 61: 7889–7899.PubMedGoogle Scholar
  19. Coronella, J.A. et al. (2002). Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J. Immunol. 169: 1829–1836.PubMedGoogle Scholar
  20. Curiel, T.J. et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10: 942–949.PubMedCrossRefGoogle Scholar
  21. Dworak, H.F. (1986). Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315: 1650–1659.CrossRefGoogle Scholar
  22. Denko, N.C. et al. (2003). Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22: 5907–5914.PubMedCrossRefGoogle Scholar
  23. Engbring, J.A. and Kleinman, H.K. (2003). The basement membrane matrix in malignancy. J. Pathol. 200: 465–470.PubMedCrossRefGoogle Scholar
  24. Ellis, L.M. and Fidler, I.J. (1996). Angiogenesis and metastasis. Eur. J. Cancer 32A: 2451–2460.PubMedCrossRefGoogle Scholar
  25. Esche, C. et al. (1999). Tumor’s other immune targets: dendritic cells. J. Leukocyte Biol. 66: 336–344.PubMedGoogle Scholar
  26. Esche, C. et al. (2001). Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome C release mediated resistance of mature dendritic cells to melanoma-induced apoptosis. Clin. Cancer Res. 7: 974s–979s.PubMedGoogle Scholar
  27. Fisher, E.R. et al. (1990). Medullary cancer of the breast revisited. Breast Cancer Res. Treat. 16: 215–229.PubMedCrossRefGoogle Scholar
  28. Furukawa, T. et al. (1985). T-zone histiocytes in adenocarcinoma of the lung in relation to postoperative prognosis. Cancer 56: 2651–2656.PubMedCrossRefGoogle Scholar
  29. Gabrilovich, D.I. et al. (1996a). Decrease in antigen presentation by dendritic cells in patients with breast cancer. Nat. Med. 2: 1096–1103.PubMedCrossRefGoogle Scholar
  30. Gabrilovich, D.I. et al. (1996b). Vascular endothelial growth factor produced by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 2: 1096–1103.PubMedCrossRefGoogle Scholar
  31. Gabrilovich, D. et al. (1999). Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell functions. Clin. Cancer Res. 5: 2963–2970.PubMedGoogle Scholar
  32. Gabrilovich, D. (2004). Mechanisms and functional significance of tumor-induced dendritic cell defects. Nature Med. 4: 941–952.Google Scholar
  33. Gallucci, S. and Matzinger, P. (2001). Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13: 114–119.PubMedCrossRefGoogle Scholar
  34. Giannini, A. et al. (1991). Prognostic significance of accessory cells and lymphocytes in nasopharygeal carcinoma. Pathol. Res. Pract. 187: 496–502.PubMedCrossRefGoogle Scholar
  35. Goldman, S.A. et al. (1998). Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch. Otolaryngol. Head Neck Surg. 124: 641–646.PubMedGoogle Scholar
  36. Greten, F.R. et al. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285–296.PubMedCrossRefGoogle Scholar
  37. Hanada, T. and Yoshimura, A. (2002). Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 13: 413–421.PubMedCrossRefGoogle Scholar
  38. Hansen, M.H. et al. (2001). The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic tumor cells. Proc. Natl Acad. Sci. U.S.A. 98: 12659–12664.PubMedCrossRefGoogle Scholar
  39. Hansson, M. et al. (1996). Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J. Immunol. 156: 42–47.PubMedGoogle Scholar
  40. Hoffmann, T.K. et al. (2002). Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin. Cancer Res. 8: 2553–2562.PubMedGoogle Scholar
  41. Janeway Jr., C.A. (1992). The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13: 11–16.PubMedCrossRefGoogle Scholar
  42. Kiessling, R. et al. (1996). Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Sem. Immunopathol. 18: 227–242.CrossRefGoogle Scholar
  43. Kornstein, M.J. et al. (1983). Immunoperoxidase localization of lymphocyte subsets in the host responses to melanoma and nevi. Cancer Res, 43: 2749–2753.PubMedGoogle Scholar
  44. Kotlan, B. et al. (2003). Immunoglobulin reprtoire of B lymphocytes infiltrating breast medullary carcinoma. Hum. Antibodies 12: 113–121.PubMedGoogle Scholar
  45. Kuss, I. et al. (1999). Clinical significance of decreased ζ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin. Cancer Res. 5: 329–334.PubMedGoogle Scholar
  46. Lanier, L.L. (2003). Natural killer cell receptor signaling. Curr. Opin. Immunol. 15: 308–314.PubMedCrossRefGoogle Scholar
  47. Lee, K.M. et al. (1998). Molecular basis of T-cell inactivation by CTLA-4. Science 282: 2263–2266.PubMedCrossRefGoogle Scholar
  48. Leek, R.D. et al. (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56: 4625–4629.PubMedGoogle Scholar
  49. Lespagnard, L. et al., (1999) Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int. J. Cancer 84: 309–314.PubMedCrossRefGoogle Scholar
  50. Li, X. et al. (1994). T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res. 54: 5424–5429.PubMedGoogle Scholar
  51. Lin, E.Y. et al. (2001). Colony-stimulating factor 1 promotes progression of mamary tumors to malignancy. J. Exp. Med. 193: 727–740.PubMedCrossRefGoogle Scholar
  52. Ling, W. et al. (1998). Impaired activation of NFκB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IκBα. Blood 92: 1334–1341.PubMedGoogle Scholar
  53. Liu, Y.J. (2001). Dendritic cell subsets and lineages and their functions in innate and adoptive immunity. Cell 106: 259–262.PubMedCrossRefGoogle Scholar
  54. Liyanage, U.K. et al. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169: 2756–2761.PubMedGoogle Scholar
  55. Malik, S.T.A. et al. (1989). Paradoxical effects of tumor necrosis factor in experimental ovarian cancer. Int. J. Cancer 44: 918–925.PubMedCrossRefGoogle Scholar
  56. Malmberg, K.J. et al. (2001). Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NK-kappaB activation. J. Immunol. 167: 2595–2601.PubMedGoogle Scholar
  57. Mareel, M. and Leroy, A. (2003). Clinical cellular, and molecular aspects of cancer invasion. Physiol. Rev. 83: 337–376.PubMedGoogle Scholar
  58. Matzinger, P. (1998). An innate sense of danger. Semin. Immunol. 10: 399–415.PubMedCrossRefGoogle Scholar
  59. May, M.J. and Ghosh, S. (1998). Signal transduction through NF-κB. Immunol. Today 19: 80–88.PubMedCrossRefGoogle Scholar
  60. Miescher, S. et al. (1987). Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J. Immunol. 138: 4004–4011.PubMedGoogle Scholar
  61. Mihm, M.C. et al. (1996). Tumor infiltrating lymphocytes in lymph node melanoma metastases — a histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 74: 43–47.PubMedGoogle Scholar
  62. Murphy, G.F. et al. (1993). Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy. J. Invest. Dermatol. 100: 335s–341s.PubMedCrossRefGoogle Scholar
  63. Naito, Y. et al. (1998). CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58: 3491–3494.PubMedGoogle Scholar
  64. Nakano, O. et al. (2001). Proliferative activity of intratumoral CD8+ T lymphocytes as aprognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res. 61: 5132–5136.PubMedGoogle Scholar
  65. Nzula, S. et al. (2003). Antigen-driven clonal proliferation, somatic hypermutation and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res. 63: 3275–3280.PubMedGoogle Scholar
  66. O’Brien, P.M. et al. (2001). Immunoglobin genes expressed by B-lymphocytes infiltrating cervical carcinomas show evidence of antigen-driven selection. Cancer Immunol. Immunother. 50: 523–532.PubMedCrossRefGoogle Scholar
  67. Otsuji, M. et al. (1996). Oxidative stress by tumor-derived macrophagessuppresses the expression of CD3 ζ chain of T-cell receptor complex and antigen-specific cell responses. Proc. Natl Acad. Sci. U.S.A. 93: 13119–13124.PubMedCrossRefGoogle Scholar
  68. Phillips, S.M. et al. (2004). Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br. J. Cancer 91: 469–475.Google Scholar
  69. Pikarsky, E. et al. (2004). NF-kappaB functions as a tumor promoter in inflammation-associated cancer. Nature 431: 461–466.PubMedCrossRefGoogle Scholar
  70. Ramsdell, F. (2003). Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 19: 165–168.PubMedCrossRefGoogle Scholar
  71. Reichert, T.E. et al. (1998a). Human immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J. Immunother. 21: 295–306.PubMedCrossRefGoogle Scholar
  72. Reichert, T.E. et al. (1998b). Absent of low expression of the ζ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 58: 5344–5347.PubMedGoogle Scholar
  73. Reichert, T.E. et al. (2001). The number of intratumoral dendritic cells and ζ-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 91: 2136–2147.PubMedCrossRefGoogle Scholar
  74. Reichert, T.E. et al. (2002). Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin. Cancer Res. 8: 3137–3145.PubMedGoogle Scholar
  75. Ribatti, D. et al. (2003). New non-angiogenesis dependent pathways for tumor growth. Eur. J. Cancer 39: 1835–1841.PubMedCrossRefGoogle Scholar
  76. Schmielau, J. and Finn, O.J. (2001). Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61: 4756–4760.PubMedGoogle Scholar
  77. Sheu, B.C. et al. (1999). Reversed CD4/CD8 percentages of tumor-infiltrating lymphocytes correlate with disease progression in human cervical cancer. Cancer 86: 1537–1543.PubMedCrossRefGoogle Scholar
  78. Shevach, E.M. (2000). Regulatory T cells in autoimmunity. Annu. Rev. Immunol. 18: 423–449.PubMedCrossRefGoogle Scholar
  79. Shevach, E.M. (2004). Fatal attraction: tumors becon regulatory T cells. Nature Med. 10: 900–901.PubMedCrossRefGoogle Scholar
  80. Shurin, M.R. et al. (1999). ‘Apoptosis in dendritic cells’ in Dendritic Cells: Biology and Clinical Applications. M.T. Lotze and A.W. Thomson (eds), Academic Press, New York, 673–692.Google Scholar
  81. Shurin, G.V. et al. (2001). Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 61: 363–369.PubMedGoogle Scholar
  82. Sitkovsky, M.V. et al. (2004). Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22: 657–682.PubMedCrossRefGoogle Scholar
  83. Stephens, G.L. et al. (2004). Engagement of glucocorticoid induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J. Immunol. 173: 5008–5020.PubMedGoogle Scholar
  84. Toi, M. (2002). Proinflammation in human tumor microenvironment: its status and implication. Med. Sci. Monit. 8: 25–26.Google Scholar
  85. Tourkova, I.L. et al. (2004). IL-15 restores MHC class I antigen processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. Submitted.Google Scholar
  86. Tsujitani, S. et al. (1987). Langerhans cells and prognosis in patients with gastric carcinoma. Cancer 59: 501–505.PubMedCrossRefGoogle Scholar
  87. Tsujitani, S. et al. (1990). Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 66: 2012–2016.PubMedCrossRefGoogle Scholar
  88. Treilleux, I. et al. (2004). Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 10: 7466–7474.PubMedCrossRefGoogle Scholar
  89. Troy, A.J. et al. (1998). Minimal recruitment and activation of dendritic cells in within renal cell carcinoma. Clin. Cancer Res. 4: 585–593.PubMedGoogle Scholar
  90. Uzzo, R.G. et al. (1999a). Renal cell carcinoma-derived gangliosides suppress NFκB activation in T cells. J. Clin. Invest. 104: 769–776.PubMedCrossRefGoogle Scholar
  91. Uzzo, R.G. et al. (1999b). Alterations in NFκB activation in T lymphocytes of patients with renal cell carcinoma. J. Nat. Cancer Inst. 91: 718–721.PubMedCrossRefGoogle Scholar
  92. Vacarello, L. et al. (1993). Tumor-infiltrating lymphocytes from ovarian tumors of low malignant potential. Int. J. Gynecol. Path. 12: 41–50.CrossRefGoogle Scholar
  93. Vitolo, D. et al. (1993). In situ hybridization for cytokine gene transcripts in the solid tumor microenvironment. Eur. J. Cancer 3: 371–377.CrossRefGoogle Scholar
  94. Von Kleist, S. et al. (1987). Immunohistochemical analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions. Int. J. Cancer 40: 18–23.CrossRefGoogle Scholar
  95. Weidmann, E. et al. (1992). The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Cancer Res. 52: 5913–5920.PubMedGoogle Scholar
  96. Weidmann, E. et al. (1993). Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. Int. J. Cancer 54: 383–390.PubMedCrossRefGoogle Scholar
  97. Whiteside, T.L. (1992). Tumor Infiltrating Lymphocytes as antitumor effector cells. Biotherapy 5: 47–61.PubMedCrossRefGoogle Scholar
  98. Whiteside, T.L. (1993). Tumor Infiltrating Lymphocytes in Human Malignancies. Medical Intelligence Unit, R.G. Landes Co., Austin, TX.Google Scholar
  99. Whiteside, T.L. et al. (1998). Natural killer cells and tumor therapy. Curr. Topics Microbiol. Immunol. 230: 221–244.Google Scholar
  100. Whiteside, T.L. and Rabinowich, H. (1998). The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol. Immunother. 46: 175–184.PubMedCrossRefGoogle Scholar
  101. Whiteside, T.L. (2002). Tumor-induced death of immune cells: its mechanisms and consequences. Sem. Cancer Biol. 12: 43–50.CrossRefGoogle Scholar
  102. Whiteside, T.L. (2004). Down-regulation of ζ chain expression in T cells: A biomarker of prognosis in cancer? Cancer Immunol. Immunother. 53: 865–876.PubMedGoogle Scholar
  103. Whiteside, T.L. et al. (2004). Antigen processing machinery (APM) in human dendritic cells: up-regulation by maturation and down regulation by tumor cells. J. Immunol. 173: 1526–1534.PubMedGoogle Scholar
  104. Whiteside, T.L. et al. (2005). ‘Tumor induced immune suppression and immune escape: Mechanisms and possible solutions’ in: Monitoring T cell Directed Vaccine Trials in Cancer Patients. D. Nagorsen and F. Manincola (eds) in press.Google Scholar
  105. Whitford, P. et al. (1990). Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer. Br. J. Cancer 62: 971–975.PubMedCrossRefGoogle Scholar
  106. Woo, E.Y. et al. (2001). Regulatory CD4+ CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late stage ovarian cancer. Cancer Res. 61: 4766–4772.PubMedGoogle Scholar
  107. Zhang, L. et al. (1997). Gene expression profiles in normal and cancer cells. Science 276: 1268–1272.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Theresa L. Whiteside
    • 1
  1. 1.University of Pittsburgh Cancer InstitutePittsburgh

Personalised recommendations